Please login to the form below

Not currently logged in
Email:
Password:

Levest COC promises NHS cost savings

Combined oral contraception, Levest, has won an NHS contract as the preferred drug of its type for hospitals in England

In addition to being listed by the majority of retail pharmacy wholesalers and multiples, Morningside Healthcare's combined oral contraception (COC), Levest, has won an NHS contract as the preferred drug of its type for hospitals in England.

Levest contains levenogesterel 150μg and ethinylestradiol 30μg and costs £2.55 per 63 tablets, or the equivalent of just £0.85 per cycle. This makes it 10 per cent cheaper than competitor, Microgynon 30 (ethinylestradiol and levonorgestrel), which costs £2.82 per 63 tablet, or £0.94 per cycle.

With an estimated one million women in England currently prescribed Microgynon, the potential cost savings for the NHS in England are in excess of £1m a year.

Dr Al-Azzawi, consultant gynaecologist, comments: "The clinical data demonstrates that Levest is bioequivalent to Microgynon 30 and can be prescribed in place of it without any loss of contraceptive efficacy."

5th May 2010

From: Healthcare

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Envision Pharma Group

We are a global leader in the medical affairs space. Our purpose-built software and scientific solutions make us a unique...

Latest intelligence

What challenges still face clinical trial recruitment and retention?
Discover the reasons for the current clinical trial recruitment challenges facing pharma and the life sciences industry, and how the search for solutions to the problem continues...
“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...

Infographics